01567nas a2200217   4500000000100000008004100001653002200042653001200064653001900076100001100095700001400106700001400120700001200134700001300146245004600159856007300205300001200278490000600290520103900296022001401335       2017                            d10aMultidrug therapy10aleprosy10aCase detection1 aNaaz F1 aMohanty P1 aBansal AK1 aKumar D1 aGupta UD00aChallenges beyond elimination in leprosy.  uhttp://www.ijmyco.org/temp/IntJMycobacteriol63222-2436908_064609.pdf  a222-2280 v63 a<p>Every year &gt;200,000 new leprosy cases are registered globally. This number has been fairly stable over the past 8 years. The World Health Organization has set a target to interrupt the transmission of leprosy globally by 2020. It is important, in terms of global action and research activities, to consider the eventuality of multidrug therapy (MDT) resistance developing. It is necessary to measure disease burden comprehensively, and contact-centered preventive interventions should be part of a global elimination strategy. Drug resistance is the reduction in effectiveness of a drug such as an antimicrobial or an antineoplastic in curing a disease or condition. MDT has proven to be a powerful tool in the control of leprosy, especially when patients report early and start prompt treatment. Adherence to and its successful completion is equally important. This paper has reviewed the current state of leprosy worldwide and discussed the challenges and also emphasizes the challenge beyond the elimination in leprosy.</p>
  a2212-554X